Lowell L. Hart, MD, FACP, discusses detection and treatment of interstitial lung disease for patients with HER2-positive breast cancer who received fam-trastuzumab deruxtecan-nxki.
Lowell L. Hart, MD, FACP
Advertisement
Articles by Lowell L. Hart, MD, FACP
Lowell L. Hart, MD, FACP, discusses the utility of antibody-drug conjugates in HER2-positive breast cancer.
Advertisement
Latest Updated Articles
Dr. Hart on Antibody-Drug Conjugates in HER2+ Breast CancerDecember 18th 2019
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
3
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
4
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
5